the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which play an important role in inflammatory and immune responses. The FDA approval of Otulfi...
Osteo Bi-Flex®, the number one pharmacist-recommended joint care supplement brand1 introduced its new Osteo Bi-Flex® Advanced Omega-3 Joint Complex supplement. This new formula helps support joint and whole body health by combining 100 mg of Joint...
to a new mechanism by which microbiome-derived compounds may help combat obesity and related diseases. The compound—HYA (10-hydroxy-cis-12-octadecenoic acid)—is made when certain gut bacteria, including Lactobacillus, metabolize linoleic acid, a...
the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in developing cutting-edge...
fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis (IPF), has been initiated with screening and recruitment...
developing innovative cancer therapies. As part of this partnership, Viralgen successfully scaled-up and completed in under 12 months a good manufacturing practice (GMP) clinical trial material batch of Trogenix's rAAV gene therapy, TGX-007,...
The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN’s project was one of several selected for their high-impact potential in areas including...
and translational results from two studies for omilancor, a Phase 3 first-in-class LANCL2 agonist versus the leading anti-TL1A candidate currently also in Phase 3 development for ulcerative colitis (“UC”). The new findings demonstrate that once...
discoveries to combat vision problems and improve people's lives." About Zeiss: Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology...
around the world with a shared commitment to reducing global greenhouse gas emissions. SK Group companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most...
on a global scale.” The initial focus of the collaboration will be the preclinical evaluation of TLS’s proprietary boron-10 drugs in cellular and animal models, leveraging Ohio State’s specialized neutron source optimized for BNCT research. In...
microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy, SNE-101. This is the first exosome-based therapy in Korea to enter...
facility featuring twin lyophilizers and a state-of-the-art large-scale isolator filling line compliant with Annex 1. That facility will be GMP ready this summer; since the plant’s 2022 groundbreaking, PCI has methodically developed...
Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National...
interim results from its first-in-human study of XmAb942. A high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn’s...
that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent neuroprotective properties Mark Bazett will be joined by Jim Pankovich, EVP Clinical Development, and Ashish Kumar,...
outcomes with transformative global implications. Broad and Effective Antibody Response: LHNVD-303 generated high-titer IgG1 antibodies in both mice and pigs against LPS, PGN, and LTA, confirming the ability to target conserved epitopes. Antisera...
both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s...
the treatment of real patients with XIAFLEX, which represents an important treatment option to help appropriate patients.1 This is the second time Endo has used the power of spatial computing (also called "mixed reality") to create an immersive...
(P=0.035) in median OS. The group treated with Optune Lua concurrently with an immune checkpoint inhibitor or docetaxel (n=137) had a median OS of 13.2 months (95% CI, 10.3 to 15.5 months) compared to a median OS of 9.9 months (95% CI, 8.2 to 11.5...